PMID- 36058855
OWN - NLM
STAT- MEDLINE
DCOM- 20220907
LR  - 20220907
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 63
IP  - 8
DP  - 2022
TI  - [Myeloid sarcomas of the shoulder and testis relapsing 9 years after allogenic 
      stem cell transplantation for acute myeloid leukemia].
PG  - 860-864
LID - 10.11406/rinketsu.63.860 [doi]
AB  - This report describes a 56-year-old man who was diagnosed with myeloid sarcoma 
      (MS) of the testis and right shoulder after receiving allogenic stem cell 
      transplantation (allo-SCT) at the age of 47 for acute myeloid leukemia (AML) with 
      inv (16) (p13.1;q22). Nine years after allo-SCT, he complained of a painful right 
      testicular mass. He underwent orchiectomy, and the pathologic diagnosis was MS. 
      Inv (16) was identified by fluorescence in situ hybridization (FISH) using 
      testicular tumor specimens. 18F-fluorodeoxyglucose (FDG) positron emission 
      tomography-computed tomography (PET-CT) revealed FDG accumulation in the right 
      shoulder. FISH analysis of bone marrow aspirate revealed no increase in blasts 
      and ruled out CBFB-MYH11 fusion. Reinduction chemotherapy, consolidation, and 
      local radiation therapy for the left testis and right shoulder were administered 
      to him. After that, he received a second allo-SCT from an unrelated donor who was 
      HLA-matched. As of 2 years after the second allo-SCT, recurrence of neither AML 
      nor myeloid sarcoma has been observed. The recurrence of MSs without bone marrow 
      involvement is frequently reported in single, multiple single organs, or multiple 
      single regions. Even if MSs recur in a distant location, combining systemic and 
      local treatment may be a better treatment strategy.
FAU - Yamamoto, Rikuo
AU  - Yamamoto R
AD  - Hematology and Oncology Division, Hitachi General Hospital.
FAU - Suyama, Takuya
AU  - Suyama T
AD  - Hematology and Oncology Division, Hitachi General Hospital.
FAU - Yoshizawa, Yuki
AU  - Yoshizawa Y
AD  - Hematology and Oncology Division, Hitachi General Hospital.
FAU - Shimizu, Misayo
AU  - Shimizu M
AD  - Hematology and Oncology Division, Hitachi General Hospital.
FAU - Kuroda, Akihiro
AU  - Kuroda A
AD  - Hematology and Oncology Division, Hitachi General Hospital.
FAU - Shinagawa, Atsushi
AU  - Shinagawa A
AD  - Hematology and Oncology Division, Hitachi General Hospital.
LA  - jpn
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Leukemia, Myeloid, Acute/drug therapy
MH  - Male
MH  - Positron Emission Tomography Computed Tomography
MH  - Recurrence
MH  - *Sarcoma, Myeloid/etiology/therapy
MH  - Shoulder/pathology
MH  - Stem Cell Transplantation
MH  - Testis/pathology
MH  - Transplantation, Homologous
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Myeloid sarcoma
OT  - Stem cell transplantation
OT  - Testis
EDAT- 2022/09/05 06:00
MHDA- 2022/09/08 06:00
CRDT- 2022/09/04 22:23
PHST- 2022/09/04 22:23 [entrez]
PHST- 2022/09/05 06:00 [pubmed]
PHST- 2022/09/08 06:00 [medline]
AID - 10.11406/rinketsu.63.860 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2022;63(8):860-864. doi: 10.11406/rinketsu.63.860.